Visão geral da empresa
A clinical stage biopharmaceutical entity, Kodiak Sciences Inc. is primarily engaged in the research, development, and commercialization of therapeutics designed to treat retinal diseases. The company operates within the Healthcare sector, specifically the Biotechnology industry, a classification that implies a focus on early-stage innovation and high-risk, high-reward drug development cycles rather than mature product sales. With a market capitalization of $2.59B and a workforce of 124 employees, the organization maintains a significant valuation despite reporting N/A for its trailing twelve-month revenue. The substantial market cap relative to the absence of reported revenue indicates that the company's market value is derived almost entirely from the potential future success of its pipeline assets, such as its lead product candidate tarcocimab tedromer (KSI-301), rather than current cash flows.
Saúde financeira
Kodiak Sciences Inc. reports N/A for revenue, a net income of $-229,967,000, and an EBITDA of $-216,060,000 over the trailing twelve months. The significant gap between the reported revenue figure (which is unavailable) and the substantial net loss reveals a cost structure dominated by research and development expenditures and operating expenses typical of clinical-stage biotechnology firms. The company's free cash flow stands at $-44,382,500, indicating a continuous consumption of cash reserves to fund ongoing operations and development activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for entities that have not yet achieved commercial sales or where revenue does not cover direct costs in the current reporting period. In terms of leverage, the company holds $209.86M in cash against $59.18M in debt, resulting in a debt-to-equity ratio of 37.60, which suggests a balance sheet that is heavily weighted towards cash liquidity rather than financial debt obligations. The current ratio of 4.72 indicates a robust short-term liquidity position, providing ample coverage for current liabilities with available liquid assets. Return on Equity is -149.5% and Return on Assets is -42.6%, metrics that reflect the temporary nature of the company's profitability during its development phase before any product approvals generate positive returns for shareholders.
Avaliação de valorização
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is listed at -12.23, a metric that implies expectations of negative earnings growth or continued losses in the upcoming fiscal periods. The price-to-book ratio is 16.37, indicating that the market values the company at a significant premium over its net asset value, likely driven by the potential intrinsic value of its intellectual property and drug pipeline. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also presented as N/A or -11.24, reflecting the difficulty in applying traditional multiple-based valuation models to a pre-revenue biotechnology firm with negative earnings. The stock trades between a 52-week high of $45.60 and a 52-week low of $1.92, with the current price position relative to this range subject to daily market fluctuations and investor sentiment regarding the company's clinical data. The beta value of 2.40 signifies that the stock's price volatility is significantly higher than that of the broader market, exposing investors to substantial price swings that often accompany the development milestones of clinical-stage assets.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between the two metrics in the current reporting period. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% payout ratio figure provided. Instead of distributing income to shareholders, the entity reinvests its limited financial resources, specifically its $209.86M cash balance, into advancing its clinical programs and securing regulatory approvals for its therapeutics. Consequently, the overall growth and income profile for Kodiak Sciences Inc. is characterized by a reliance on capital markets for funding and a total absence of current income generation or shareholder distributions from dividends.